E Fund Management Co. Ltd. Purchases 6,335 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

E Fund Management Co. Ltd. increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 152.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,479 shares of the company's stock after acquiring an additional 6,335 shares during the quarter. E Fund Management Co. Ltd.'s holdings in Vaxcyte were worth $858,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of PCVX. Janus Henderson Group PLC boosted its stake in Vaxcyte by 23.1% during the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock worth $1,247,954,000 after acquiring an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. raised its holdings in Vaxcyte by 5.9% during the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock worth $992,914,000 after buying an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Vaxcyte by 47.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company's stock worth $148,075,000 after buying an additional 419,600 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Vaxcyte during the third quarter worth $41,114,000. Finally, Franklin Resources Inc. raised its holdings in Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock worth $315,162,000 after buying an additional 324,560 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

Remove Ads

Vaxcyte Price Performance

Shares of PCVX stock traded up $0.96 on Tuesday, hitting $69.85. The stock had a trading volume of 973,145 shares, compared to its average volume of 1,190,000. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The business has a 50 day moving average of $83.06 and a 200 day moving average of $94.66. The stock has a market cap of $8.99 billion, a price-to-earnings ratio of -15.18 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. As a group, research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now owns 7,175 shares of the company's stock, valued at $610,664.25. This represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 54,250 shares of company stock worth $4,550,258 over the last quarter. 3.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have weighed in on PCVX. Guggenheim restated a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a report on Friday, December 20th. They set a "buy" rating and a $135.00 price objective on the stock. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and an average price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.